3F

Q linea ABFRA Q linea Stock Report

Last reporting period 30 Jun, 2024

Updated 12 Nov, 2024

Last price

Market cap $B

0.033

Micro

Exchange

XFRA - Deutsche Boerse AG

3F8.F Stock Analysis

3F

Uncovered

Q linea AB is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-19/100

Low score

Market cap $B

0.033

Dividend yield

Shares outstanding

29.209 B

Q-linea AB operates as a holding company. The company is headquartered in Uppsala, Uppsala. The company went IPO on 2018-12-07. The firm develops and manufactures in-vitro diagnostic (IVD) solutions for infectious diseases. The firm's core product candidate is ASTar, a fully-automated instrument for Antibiotic Susceptibility Testing (AST). The company measures bacteria's antimicrobial susceptibility using the disposables developed by the Company. The company is able to provide a susceptibility profile within three to six hours directly from a positive blood culture, which enables early administration of antibiotics specifically targeting the disease-causing pathogen. Its main application is the identification of sepsis in hospital patients and the product is aimed primarily at hospital laboratories.

View Section: Eyestock Rating